Azenta repays $35 million secured vendor loan from B Medical Systems sale

BURLINGTON, Mass., Sept. 4, 2026 /CourierPR/ -- Azenta, Inc. (Nasdaq: AZTA) has completed the full repayment of a $35 million secured vendor loan, which was part of the sale of B Medical Systems S.à r.l. to Thelema S.à r.l. on July 1, 2026. The transaction marks a significant step in Azenta’s ongoing strategy to manage its capital resources and support its growth initiatives.

As part of the deal, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, entered into a Vendor Loan Agreement with Thelema S.à r.l. The agreement involved Azenta Germany providing a secured term loan to Thelema S.à r.l. in the amount of $35 million. The loan was secured by a pledge over the equity interests of B Medical Systems. With the repayment of the loan, Azenta has now received the entire $63 million purchase price in cash, effectively retiring the credit exposure associated with the transaction.

Dr. Martin D. Madaus, Interim President and Chief Executive Officer of Azenta, commented, “The repayment of the vendor loan completes the divestiture of B Medical Systems. Azenta has now received the entire purchase price in cash, supporting our disciplined approach to capital allocation.”

Azenta, a global leader in life sciences solutions, offers a comprehensive range of services and products designed to accelerate the development and delivery of breakthrough therapies. The company’s portfolio includes reliable cold-chain sample management solutions and multiomics services, catering to the needs of top pharmaceutical, biotech, academic, and healthcare institutions worldwide.

Azenta is headquartered in Burlington, Massachusetts, with operations spanning North America, Europe, and Asia. The company’s commitment to innovation and customer service is exemplified through its industry-leading brands, such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

The completion of this transaction reflects Azenta’s strategic focus on optimizing its financial position and capital allocation. With the cash received, the company can now focus on furthering its mission to enable faster innovation and breakthroughs in the life sciences industry.